Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s charts are FTSE 100, Dax, Dow, Bitcoin, Gold, Alpha Growth,
Avacta Group PLC ((AIM:AVCT) First Quarter of 2025 Outlining Progress Against Strategic Objectives
AVA6000 Phase 1b expansion cohorts enrolling with data targeted for later in 2025 AVA6103 IND-enabling studies underway with a Phase 1 trial anticipated to begin in the first quarter
Avacta Group PLC (AIM:AVCT) Avacta Announces Presentations at AACR
Avacta Therapeutics Announces Presentations at 2025 AACR Annual Meeting
Avacta Group PLC (AIM:AVCT) Avacta to Present at Leerink Healthcare Conference
Avacta Therapeutics to Present at the 2025 Leerink Global Healthcare Conference
Avacta Group PLC (AIM:AVCT) Agreement to Sell Launch Diagnostics and a Corporate Update
Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, announces that it has agreed to sell
Avacta Group PLC (AIM:AVCT) Avacta Announces Data from AVA6000 Phase 1 trial
Avacta Announces Positive New Data from the AVA6000 Phase 1 trial Demonstrating Clinically Meaningful Tumor Shrinkage in Patients with Salivary Gland Cancers
Avacta Group PLC (AIM:AVCT) Appoints Brian Hahn as Chief Financial Officer
Brian brings 25 years’ senior financial and operational experience, including leading GlycoMimetics’ Nasdaq IPO and financial operations
Avacta Group (AIM:AVCT) Leading the Way in Precision Cancer Therapies
Avacta Group (AIM: AVCT) is redefining cancer treatment through its proprietary pre|CISION™ platform, which enables the development of peptide drug conjugates (PDCs) that deliver chemotherapy drugs directly to tumours.
Avacta’s progress with AVA6000 and the pre|CISION™ platform positions it as a standout in precision medicine.
Avacta Group (AIM: AVCT) is redefining cancer treatment through its proprietary pre|CISION™ platform, which enables the development of peptide drug conjugates (PDCs) that deliver chemotherapy drugs directly to tumours.
Exploration, Innovation, and Growth: 20 Small-Caps to Watch in 2025 – Part 1
The London Stock Exchange is home to a vast array of small-cap companies, each offering unique opportunities and challenges for retail investors. As we head into 2025, this two-part series
Avacta Group (AIM:AVCT) Leading the Way in Precision Cancer Therapies
Avacta Group (AIM: AVCT) is redefining cancer treatment through its proprietary pre|CISION™ platform, which enables the development of peptide drug conjugates (PDCs) that deliver chemotherapy drugs directly to tumours.
Avacta Group PLC (AIM:AVCT) Completion of Dose Escalation and RDE Arms
Dose Escalation and Recommended Dose for Expansion (RDE) Arms of the AVA6000 Phase 1a Trial complete and Phase 1b Disease Specific Expansion Cohorts Open for Enrolment